Evidence map›Paper›PMID 35715841›Full record

ArticleStem cell research & therapy2022

Human umbilical cord-derived mesenchymal stem cells not only ameliorate blood glucose but also protect vascular endothelium from diabetic damage through a paracrine mechanism mediated by MAPK/ERK signaling.

Yi Liu, Jingan Chen, Haowei Liang, Yueqin Cai, Xinyue Li, Li Yan, Li Zhou, Letian Shan, Hui Wang

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 2 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. MAP kinase phosphatases in metabolic diseases.Trends in endocrinology and metabolism: TEM · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yi Liu *School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Jingan Chen *School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Haowei LiangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Yueqin CaiSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Xinyue LiSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Li YanThe First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Li ZhouThe First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Letian ShanThe First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China. letian.shan@zcmu.edu.cn.
Hui WangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China. wh@zcmu.edu.cn.ORCID 0000-0003-0108-8254
Zhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndothelial damage is an initial step of macro- and micro-vasculature dysfunctions in diabetic patients, accounting for a high incidence of diabetic vascular complications, such as atherosclerosis, nephropathy, retinopathy, and neuropathy. However, clinic lacks effective therapeutics targeting diabetic vascular complications. In field of regenerative medicine, mesenchymal stem cells, such as human umbilical cord-derived MSCs (hucMSCs), have great potential in treating tissue damage.

methodsTo determine whether hucMSCs infusion could repair diabetic vascular endothelial damage and how it works, this study conducted in vivo experiment on streptozotocin-induced diabetic rat model to test body weight, fasting blood glucose (FBG), serum ICAM-1 and VCAM-1 levels, histopathology and immunohistochemical staining of aorta segments. In vitro experiment was further conducted to determine the effects of hucMSCs on diabetic vascular endothelial damage, applying assays of resazurin staining, MTT cell viability, wound healing, transwell migration, and matrigel tube formation on human umbilical vein endothelial cells (HUVECs). RNA sequencing (RNAseq) and molecular experiment were conducted to clarify the mechanism of hucMSCs.

resultsThe in vivo data revealed that hucMSCs partially restore the alterations of body weight, FBG, serum ICAM-1 and VCAM-1 levels, histopathology of aorta and reversed the abnormal phosphorylation of ERK in diabetic rats. By using the conditioned medium of hucMSCs (MSC-CM), the in vitro data revealed that hucMSCs improved cell viability, wound healing, migration and angiogenesis of the high glucose-damaged HUVECs through a paracrine action mode, and the altered gene expressions of IL-6, TNF-α, ICAM-1, VCAM-1, BAX, P16, P53 and ET-1 were significantly restored by MSC-CM. RNAseq incorporated with real-time PCR and Western blot results clarified that high glucose activated MAPK/ERK signaling in HUVECs, while MSC-CM reversed the abnormal phosphorylation of ERK and overexpressions of MKNK2, ERBB3, MYC and DUSP5 in MAPK/ERK signaling pathway.

conclusionsHucMSCs not only ameliorated blood glucose but also protected vascular endothelium from diabetic damage, in which MAPK/ERK signaling mediated its molecular mechanism of paracrine action. Our findings provided novel knowledge of hucMSCs in the treatment of diabetes and suggested a prospective strategy for the clinical treatment of diabetic vascular complications.

Indexed as

Blood GlucoseDiabetes Mellitus, ExperimentalDiabetic AngiopathiesMAP Kinase Signaling SystemMesenchymal Stem CellsAnimalsBody WeightEndothelium, VascularHumansHuman Umbilical Vein Endothelial CellsIntercellular Adhesion Molecule-1Mesenchymal Stem Cell TransplantationProspective StudiesRatsUmbilical CordVascular Cell Adhesion Molecule-1Blood GlucoseIntercellular Adhesion Molecule-1Vascular Cell Adhesion Molecule-1Diabetic vascular complicationsEndothelial damageHuman umbilical cord-derived mesenchymal stem cellsMAPK/ERK signalingParacrine

Identifiers

PMID35715841
PMCPMC9205155
OpenAlexW4283019040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.